Spots Global Cancer Trial Database for Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Official Title: Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Study ID: NCT02802267
Conditions
Study Description
Brief Summary: Evaluate the effect of the addition of inecalcitol to decitabine treatment on overall survival in previously untreated AML patients aged 65 years or more who are randomly assigned to receive decitabine with or without inecalcitol.
Detailed Description:
Keywords
Eligibility
Minimum Age: 65 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scripps Health, San Diego, California, United States
Georgia Cancer Center-Augusta University, Augusta, Georgia, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Duke Cancer Institute, Duke Univ Medical Center, Durham, North Carolina, United States
University of Texas; M D Anderson Cancer Center, Houston, Texas, United States
ProHealth Care Inc, Waukesha, Wisconsin, United States
Necker Hospital- APHP, Paris, , France
Contact Details
Name: Jean-Francois Dufour-Lamartinie, MD
Affiliation: Hybrigenics Corporation
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
